- Samsung Biologics received the Sustainability Leadership Award and was named “Best in Class” for Cultural Fit at the 2026 CDMO Leadership Awards.
- The recognition, presented during DCAT Week in New York, reflects client feedback and jury evaluation of sustainability practices and partnership alignment.
Samsung Biologics announced it has received multiple recognitions at the 2026 CDMO Leadership Awards, presented by Outsourced Pharma and Life Science Connect. The company was awarded the Sustainability Leadership Award, a jury-selected distinction, and was also named “Best in Class” for Cultural Fit in the ‘Biologics—Large CDMOs’ category. The awards were presented during a ceremony held in New York alongside DCAT Week.
The CDMO Leadership Awards are based on global client feedback evaluating contract manufacturing organizations across areas such as facilities, innovation, technical expertise, and manufacturing capabilities. In addition to survey-based rankings, jury awards are determined by an independent panel of industry experts using survey data and broader industry input.
Samsung Biologics stated that the recognition reflects its ongoing efforts to maintain sustainable and resilient operations that support client programs. The company has been consistently recognized in the awards, supported by client feedback highlighting execution and service quality.
“Sustainability is a core value at Samsung Biologics and guides how we pursue excellence throughout our business and partnerships.”
John Rim, President and CEO of Samsung Biologics
The company also reported recent sustainability-related developments, including achieving a Platinum rating from EcoVadis and implementing a product carbon footprint system validated for emissions measurement. Samsung Biologics continues its involvement in the Sustainable Markets Initiative and plans to further engage with global suppliers on decarbonization and value chain resilience.
